{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T01:14:23Z","timestamp":1765156463411,"version":"3.46.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82403143"],"award-info":[{"award-number":["82403143"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01973-9","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T01:13:16Z","timestamp":1765156396000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Machine learning model of clinical laboratory data for 30-day mortality of patients with hodgkin\u2019s lymphoma in ICU: a retrospective study based on MIMIC-IV database"],"prefix":"10.1007","volume":"26","author":[{"given":"Minghui","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingyu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingguo","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Limin","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"issue":"4","key":"1973_CR1","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/s41375-021-01204-6","volume":"35","author":"MA Weniger","year":"2021","unstructured":"Weniger MA, Kuppers R. Molecular biology of Hodgkin lymphoma. Leukemia. 2021;35(4):968\u201381.","journal-title":"Leukemia"},{"issue":"2","key":"1973_CR2","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1200\/JCO.21.01281","volume":"41","author":"LM Fornecker","year":"2023","unstructured":"Fornecker LM, et al. Brentuximab vedotin plus AVD for first-line treatment of early-stage unfavorable hodgkin lymphoma (BREACH): a multicenter, open-label, randomized, phase II trial. J Clin Oncol. 2023;41(2):327\u201335.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1973_CR3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1470-2045(20)30601-X","volume":"22","author":"P Borchmann","year":"2021","unstructured":"Borchmann P, et al. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(2):223\u201334.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1973_CR4","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/S1470-2045(18)30784-8","volume":"20","author":"RO Casasnovas","year":"2019","unstructured":"Casasnovas RO, et al. PET-adapted treatment for newly diagnosed advanced hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol. 2019;20(2):202\u201315.","journal-title":"Lancet Oncol"},{"issue":"31","key":"1973_CR5","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1200\/JCO.19.00964","volume":"37","author":"M Fuchs","year":"2019","unstructured":"Fuchs M, et al. Positron emission Tomography-guided treatment in early-stage favorable hodgkin lymphoma: final results of the International, randomized phase III HD16 trial by the German hodgkin study group. J Clin Oncol. 2019;37(31):2835\u201345.","journal-title":"J Clin Oncol"},{"issue":"21","key":"1973_CR6","doi-asserted-by":"publisher","first-page":"5041","DOI":"10.7150\/jca.29308","volume":"10","author":"Z Kral","year":"2019","unstructured":"Kral Z, et al. Treatment of relapsed\/refractory Hodgkin lymphoma: real-world data from the Czech Republic and Slovakia. J Cancer. 2019;10(21):5041\u20138.","journal-title":"J Cancer"},{"issue":"5","key":"1973_CR7","doi-asserted-by":"publisher","first-page":"342","DOI":"10.14735\/amko2016342","volume":"29","author":"H Mocikova","year":"2016","unstructured":"Mocikova H. Treatment of relapsed and refractory Hodgkin lymphoma \u2013 recommendations of the Czech Hodgkin Lymphoma Study Group. Klin Onkol. 2016;29(5):342\u20136.","journal-title":"Klin Onkol"},{"issue":"6","key":"1973_CR8","doi-asserted-by":"publisher","first-page":"424","DOI":"10.14735\/amko2014424","volume":"27","author":"H Mocikova","year":"2014","unstructured":"Mocikova H, et al. [Treatment and prognosis of relapsed or refractory hodgkin lymphoma patients ineligible for stem cell transplantation]. Klin Onkol. 2014;27(6):424\u20138.","journal-title":"Klin Onkol"},{"issue":"1","key":"1973_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-024-03108-6","volume":"43","author":"J Velasco-Suelto","year":"2024","unstructured":"Velasco-Suelto J, et al. Hodgkin lymphoma and liquid biopsy: a story to be told. J Exp Clin Cancer Res. 2024;43(1):184.","journal-title":"J Exp Clin Cancer Res"},{"key":"1973_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2023.137082","volume":"797","author":"D Fayette","year":"2023","unstructured":"Fayette D, et al. Cognitive impairment associated with Hodgkin\u2019s lymphoma and chemotherapy. Neurosci Lett. 2023;797:137082.","journal-title":"Neurosci Lett"},{"issue":"2","key":"1973_CR11","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1177\/10781552221105572","volume":"29","author":"L Bonhomme-Faivre","year":"2023","unstructured":"Bonhomme-Faivre L, Guarino V, Misra SC. Nivolumab-induced pneumonitis and cardiopathy in a patient with relapsed Hodgkin\u2019s lymphoma. J Oncol Pharm Pract. 2023;29(2):479\u201383.","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"1973_CR12","volume":"8","author":"WT Wu","year":"2021","unstructured":"Wu WT, et al. Data mining in clinical big data: the frequently used databases, steps, and methodological models. Mil Med Res. 2021;8(1):44.","journal-title":"Mil Med Res"},{"issue":"4","key":"1973_CR13","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3233\/CBM-160336","volume":"19","author":"J Ding","year":"2017","unstructured":"Ding J, Karp JE, Emadi A. Elevated lactate dehydrogenase (LDH) can be a marker of immune suppression in cancer: interplay between hematologic and solid neoplastic clones and their microenvironments. Cancer Biomark. 2017;19(4):353\u201363.","journal-title":"Cancer Biomark"},{"key":"1973_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.753712","volume":"11","author":"J Qi","year":"2021","unstructured":"Qi J, et al. Elevated lactate dehydrogenase levels display a poor prognostic factor for non-Hodgkin\u2019s lymphoma in intensive care unit: an analysis of the MIMIC-III database combined with external validation. Front Oncol. 2021;11:753712.","journal-title":"Front Oncol"},{"issue":"9","key":"1973_CR15","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1200\/JCO.23.01115","volume":"42","author":"T Aoki","year":"2024","unstructured":"Aoki T, et al. Spatially resolved tumor microenvironment predicts treatment outcomes in relapsed\/refractory hodgkin lymphoma. J Clin Oncol. 2024;42(9):1077\u201387.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1973_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/cc11396","volume":"16","author":"ME Ong","year":"2012","unstructured":"Ong ME, et al. Prediction of cardiac arrest in critically ill patients presenting to the emergency department using a machine learning score incorporating heart rate variability compared with the modified early warning score. Crit Care. 2012;16(3):R108.","journal-title":"Crit Care"},{"issue":"1","key":"1973_CR17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41580-021-00407-0","volume":"23","author":"JG Greener","year":"2022","unstructured":"Greener JG, et al. A guide to machine learning for biologists. Nat Rev Mol Cell Biol. 2022;23(1):40\u201355.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"20","key":"1973_CR18","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1161\/CIRCULATIONAHA.115.001593","volume":"132","author":"RC Deo","year":"2015","unstructured":"Deo RC. Machine learning in medicine. Circulation. 2015;132(20):1920\u201330.","journal-title":"Circulation"},{"key":"1973_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2016.35","volume":"3","author":"AE Johnson","year":"2016","unstructured":"Johnson AE, et al. MIMIC-III, a freely accessible critical care database. Sci Data. 2016;3:160035.","journal-title":"Sci Data"},{"key":"1973_CR20","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2023.5509","author":"Y Che","year":"2023","unstructured":"Che Y, et al. Advances in the treatment of Hodgkin\u2019s lymphoma (Review). Int J Oncol. 2023.62(5).","journal-title":"Int J Oncol"},{"issue":"2","key":"1973_CR21","volume":"4","author":"P Nagpal","year":"2021","unstructured":"Nagpal P, Descalzi-Montoya DB, Lodhi N. The circuitry of the tumor microenvironment in adult and pediatric Hodgkin lymphoma: cellular composition, cytokine profile, EBV, and exosomes. Cancer Rep. 2021;4(2):e1311.","journal-title":"Cancer Rep"},{"issue":"21","key":"1973_CR22","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","volume":"339","author":"D Hasenclever","year":"1998","unstructured":"Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin\u2019s disease. International prognostic factors project on advanced Hodgkin\u2019s disease. N Engl J Med. 1998;339(21):1506\u201314.","journal-title":"N Engl J Med"},{"issue":"10","key":"1973_CR23","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1182\/blood-2012-06-439455","volume":"121","author":"G Venkataraman","year":"2013","unstructured":"Venkataraman G, et al. Aberrant T-cell antigen expression in classical Hodgkin lymphoma is associated with decreased event-free survival and overall survival. Blood. 2013;121(10):1795\u2013804.","journal-title":"Blood"},{"issue":"3","key":"1973_CR24","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1053\/j.seminhematol.2016.05.003","volume":"53","author":"PJ Brockelmann","year":"2016","unstructured":"Brockelmann PJ, Angelopoulou MK, Vassilakopoulos TP. Prognostic factors in Hodgkin lymphoma. Semin Hematol. 2016;53(3):155\u201364.","journal-title":"Semin Hematol"},{"issue":"5","key":"1973_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0285766","volume":"18","author":"L Lin","year":"2023","unstructured":"Lin L, Wang D, Chen H. The characteristics and survival of second primary lung cancer after Hodgkin\u2019s lymphoma: a comparison with first primary lung cancer using the SEER database. PLoS One. 2023;18(5):e0285766.","journal-title":"PLoS One"},{"issue":"2","key":"1973_CR26","doi-asserted-by":"publisher","first-page":"417","DOI":"10.31557\/APJCP.2023.24.2.417","volume":"24","author":"D Kadkhoda","year":"2023","unstructured":"Kadkhoda D, et al. Prognostic factors for the long-term survival after hematopoietic stem cell transplantation in patients with Hodgkin lymphoma. Asian Pac J Cancer Prev. 2023;24(2):417\u201323.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"1973_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jped.2022.05.004","volume":"99","author":"BO Silva","year":"2023","unstructured":"Silva BO, et al. Increased expression of matrix metalloproteinases 2 and 9 as poor prognosis factor for hodgkin\u2019s lymphoma patients. J Pediatr (Rio J). 2023;99(1):59\u201364.","journal-title":"J Pediatr (Rio J)"},{"issue":"2","key":"1973_CR28","first-page":"116","volume":"68","author":"S Shanbhag","year":"2018","unstructured":"Shanbhag S, Ambinder RF. Hodgkin lymphoma: a review and update on recent progress. CA Cancer J Clin. 2018;68(2):116\u201332.","journal-title":"CA Cancer J Clin"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01973-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01973-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01973-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T01:13:17Z","timestamp":1765156397000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01973-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1973"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01973-9","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"assertion":[{"value":"27 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"To facilitate public access to this valuable resource, the Institutional Review Boards of the Massachusetts Institute of Technology (No. 0403000206) and the Beth Israel Deaconess Medical Center (2001-P-001699\/14) granted public authorization. Our authors (Lingyu Xu, Zheng Xu) obtained the requisite access approval (Certification Number 37851920) and retrieved the data in October 2021.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"53"}}